Updates of Immunotherapy on Renal Cell Carcinoma

YANG Kang; LI Youyuan; YU Junfeng; WEI Shaozhong

doi:10.3971/j.issn.1000-8578.2015.09.015

Cancer Research on Prevention and Treatment > 2015 > 42(09): 929-932. > DOI: 10.3971/j.issn.1000-8578.2015.09.015

YANG Kang, LI Youyuan, YU Junfeng, WEI Shaozhong. Updates of Immunotherapy on Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 929-932. DOI: 10.3971/j.issn.1000-8578.2015.09.015

Citation:

PDF (1514 KB)

Updates of Immunotherapy on Renal Cell Carcinoma

1. Department of Urology, Renming Hospital to China Three Gorges University, Yichang 443000, China; 2. Department of Gastro-intestinal Surgery and Urological Surgery, Hubei Cancer Hospital, Wuhan 430079, China

More Information

Received Date: March 11, 2015
Revised Date: June 09, 2015

Graphical Abstract

Abstract

Abstract

Renal cell carcinoma(RCC) is a common malignancy in adult males which has a high incidence and mortality rate. Immunotherapy is initially intended to activate the immune system to induce objective responses and disease stabilization. However, the high dose treatment has severe adverse effects which limit its clinical application. The development of targeted therapy turns out to be a novel approach for RCC therapy. Nevertheless, further investigations have demonstrated that single-agent therapy with either immune or targeted agents are difficult to achieve satisfied outcomes. Thus, future direction is to combine the use of immune and targeted drugs. This article briefly reviews the basic immunology research which allows readers to comprehensively compare and contrast different immunotherapy approaches on RCC.
- Renal cell carcinoma(RCC),
- Immunotherapy,
- Dendritic cell vaccine,
- Adoptive cell immunotherapy

FullText(HTML)

References (37)

References

[1]	Slegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
[2]	Reiter MA, Kurosch M, Haferkamp A. Renal cell carcinoma. Drug therapy and prognostic models[J]. Urologe A, 2015, 54(5): 73 5-48.
[3]	Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 25 5 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy[J]. J Clin Oncol, 19 95, 13(3): 688-96.
[4]	Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 20 06, 24(1): 16-24.
[5]	Wolf B, Schwarzer A, Côté AL, et al. Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-alpha and dendritic cell vaccine[J]. PLoS One, 2012, 7(12): e50221.
[6]	Lam ET, WongMK, Agarwal N, et al. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma[J]. J Immunother, 2014, 37(7): 360-5.
[7]	Hanzl YM, Aboumohamed A, Yarlagadda N, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience[J]. Urology, 2014, 83(5): 1129-34.
[8]	Muhitch JB, Schwaab T. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?[J]. Immunotherapy, 2014, 6(9): 955-8.
[9]	Eto M, Kamba T, Miyake H, et al. STAT3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma [J]. Eur Urol, 2013, 63(4): 745-52.
[10]	Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis - Results of a randomized controlled trial[J]. Cancer, 20 07, 110(11): 2468-77.
[11]	Messing EM, Manola J, Wilding G, et al. Phase Ⅲ study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial[J]. J Clin Oncol, 2003, 21(7): 1214-22.
[12]	Passalacqua R, Caminiti C, Buti S, et al. Adjuvant Low- Dose Interleukin-2 (IL-2) Plus Interferon-alpha (IFN-alpha) in Operable Renal Cell Carcinoma (RCC): A Phase Ⅲ, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC)[J]. J Immunother, 2014, 37(9): 440-7.
[13]	Rini BI, Halabi S, Rosenberg JE, et al. Phase Ⅲ trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206[J]. J Clin Oncol, 2010, 28(13): 2137-43.
[14]	Escudier B, Bellmunt J, Négrier S, et al. Phase Ⅲ trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival[J]. J Clin Oncol, 2010, 28(13): 2144-50.
[15]	Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 12 5-34.
[16]	Matsushita H, Kakimi K, Tomita Y, et al. Exploring immune therapy for renal cancer[J]. Int J Urol, 2011, 18(6): 412-21.
[17]	Godwin JL, Zibelman M, Plimack ER, et al. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials[J]. Discov Med, 2014, 18 (101): 341-50.
[18]	Birkhauser FD, Koya RC, Neufeld C, et al. Dendritic cellbased immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models[J]. J Immunother, 2013, 36(2): 10 2-11.
[19]	Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis[J]. PLoS One, 2011, 6(4): e18801.
[20]	Leonhartsberger N, Ramoner R, Falkensammer C, et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma[J]. Cancer Immunol Immunother, 2012, 61(9): 14 07-13.
[21]	Flörcken A, Kopp J, van Lessen A, et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study[J]. Hum Vaccin Immunother, 2013, 9(6): 1217-27.
[22]	Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival[J]. Nat Med, 2012, 18(8): 1254-61.
[23]	Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma[J]. Expert Opin Investiga Drugs, 2013, 22(10): 13 29-36.
[24]	May M, Brookman-May S, Hoschke B, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting[J]. Cancer Immunol Immunother, 2010, 59(5): 687-95.
[25]	Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor[J]. Cytotherapy, 2012, 14(1): 80-90.
[26]	Rosenberg SA, Yang JC, Sherry RM, et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy[J]. Clin Cancer Res, 2011, 17(13): 4550-7.
[27]	Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J]. Clin Cancer Res, 2012, 18(6): 1751-9.
[28]	Rosenberg SA. IL-2: the first effective immunotherapy for human cancer[J]. J Immunol, 2014, 192(12): 5451-8.
[29]	Bedke J, Gouttefangeas C, Singh-Jasuja H, et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy[J]. World J Urol, 2014, 32(1): 31-8.
[30]	Han X, Shang D, Han T, et al. Interferon-alpha enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity[J]. Exp Ther Med, 2014, 8(1): 267-73.
[31]	Amin A, Dudek A, Logan T, et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)[J]. J Clin Oncol, 2013, 31(6).
[32]	FIGLIN RA, WOOD C G, GRP AS. ADAPT: An ongoing international phase Ⅲ randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC)[J]. J Clin Oncol, 2014, 32(4).
[33]	Procopio G, Verzoni E, Bracarda S, et al. Sorafenib with interleukin- 2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial[J]. Br J Cancer, 2011, 104(8): 1256-61.
[34]	Procopio G, Verzoni E, Bracarda S, et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial[J]. Ann Oncol, 2013, 24(12): 2967-71.
[35]	Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer[J]. Nature, 2014, 515(7528): 558-62.
[36]	Hammers H, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)[J]. Bju International, 2014, 114: 8.
[37]	Harshman LC, Drake CG, Wargo JA, et al. Cancer Immunotherapy Highlights from the 2014 ASCO Meeting[J]. Cancer Immunol Res, 2014, 2(8): 714-9.

[1]	WANG Jingyi, ZHONG Yuling, WU Lin. Immunotherapy for Advanced Non-small Cell Lung Cancer: Research Progress and Perspectives[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 409-418. DOI: 10.3971/j.issn.1000-8578.2024.24.0090
[2]	ZHENG Jianhong, TIAN Lin, ZHAO Peiyan, LI Hui, CHENG Ying. Research Progress on Efficacy-related Biomarkers of Immunotherapy in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 127-133. DOI: 10.3971/j.issn.1000-8578.2024.23.0856
[3]	WU Hui, SUN Lina, PAN Zhangchi, SHI Chunmei. Prediction of Responses of Patients with Hepatocellular Carcinoma to Anti-PD-1 Immunotherapy by T-cell Invigoration to Tumour Burden Ratio[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1103-1108. DOI: 10.3971/j.issn.1000-8578.2023.23.0375
[4]	SUN Yichu, LIANG Fei, XIA Youyou. Progress of Research on Radiotherapy Combined with Immunotherapy for Brain Metastases from Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 705-709. DOI: 10.3971/j.issn.1000-8578.2023.22.1322
[5]	SU Chunxia, YU Xin. Advances of Immunotherapy for Non-small Cell Lung Cancer with Driver Gene Mutations[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 1-5. DOI: 10.3971/j.issn.1000-8578.2023.22.1033
[6]	FU Yongliang, HUANG Wenting. Current Status of Immunotherapy for B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(2): 159-162. DOI: 10.3971/j.issn.1000-8578.2022.21.0857
[7]	CHENG Ying. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 745-750. DOI: 10.3971/j.issn.1000-8578.2021.21.0472
[8]	YI Ping, ZHANG Zhiming, LIN Jiayao, REN Yuan, OUYANG Gaoxiong, LIU Chunhui, FENG Zhongxu, LV Qingjie, LIU Jianyong. Immunological Competence of Dendritic Cell Vaccine Loaded with CD133+ Hepatocellular Carcinoma Cell RNA[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 184-188. DOI: 10.3971/j.issn.1000-8578.2017.03.006
[9]	Wang Li, Gao Quanli, Wang Zibing, Fu Xiaomin, Zhang Xiaojie, Xu Benling, Zhang Xuhua, Zhang Yong, Yang Yonghao, Liu Yuqing, Song Yongping. Clinical Efficacy of Autologous CIK Cell Adoptive Immunotherapy Combined with Chemotherapy in Patients Withmetastatic Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 722-724. DOI: 10.3971/j.issn.1000-8578.2012.06.028
[10]	DONG Zhen, NIU Hong-quan, DONG Fang-yong, LI Chun-lin, LEI Ting, XUE De-lin. Alterations of T Cell Subpopulation in Gl ioma Patients Received Autologous Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2005, 32(12): 782-784. DOI: 10.3971/j.issn.1000-8578.1542

Cited By

Get Citation

PDF

XML

Article views (1672) PDF downloads (2039)

Turn off MathJax

Article Contents

Abstract

References

Updates of Immunotherapy on Renal Cell Carcinoma

Abstract

References

Related Articles

Catalog

Contact Us

Updates of Immunotherapy on Renal Cell Carcinoma

Abstract

References

Related Articles

Catalog

Contact Us

Export File

Citation

Format

Content